Simplify Logo

Full-Time

Principal Scientist/Associate Director

Medicinal Chemistry

Posted on 6/27/2024

Cytokinetics

Cytokinetics

201-500 employees

Develops drugs for muscle function improvement

Hardware
Biotechnology
Healthcare

Compensation Overview

$195k - $239kAnnually

Expert

San Bruno, CA, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • Doctorate level degree in relevant area of chemistry
  • 10+ years of relevant experience developing small molecule drugs within the pharmaceutical industry
  • Prior experience in Targeted Protein Degradation
  • High level of synthetic chemistry expertise
  • Minimum 5+ years experience managing and developing scientists
  • Good understanding of key research and development technical areas
  • Experience collaborating with and leading teams of internal/CRO staff scientists
  • Strong record of peer-reviewed scientific publications and presentations
  • Highly organized with excellent communication skills
Responsibilities
  • Lead research project teams with scientific excellence
  • Build well-connected teams focused on solving key research problems
  • Progress research projects through literature research and hands-on experimentation
  • Manage scalable routes for potential development compounds
  • Develop a robust small molecule portfolio aligned with company vision
  • Collaborate with functional area leaders to ensure efficient workflows
  • Mentor and support career development of colleagues
  • Oversee safe working practices within the lab
  • Communicate research through publications and presentations

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

21%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.
INACTIVE